Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
PSTV
$0.28
$
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Next Earnings
2026-02-25
Beta
0.854
Average Volume
Market Cap
Last Dividend
CIK
0001095981
ISIN
US72941H5090
CUSIP
72941H400
CEO
Marc H. Hedrick
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
21
IPO Date
2001-07-11
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Plus Therapeutics, Inc. (PSTV) Discusses Business Update, REYOBIQ Clinical Program Progress, and Recent Financial Offering Transcript | Plus Therapeutics, Inc. (PSTV) Discusses Business Update, REYOBIQ Clinical Program Progress, and Recent Financial Offering Transcript | Seeking Alpha | 2026-01-22 11:34:43 |
| Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET | HOUSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that the Company will provide a business update on Thursday, January 22, 2026 before the market open. Plus Therapeutics' management team will then host a conference call and webcast at 9:00 a.m. ET to discuss and provide additional details. | GlobeNewsWire | 2026-01-21 16:15:00 |
| Penny Cancer Stock Plus Therapeutics Raises $15 Million At Discount, Stock Plunges | Plus Therapeutics Inc. (NASDAQ: PSTV) stock is down during trading session on Wednesday following the company's announcement of a public offering. | Benzinga | 2026-01-14 11:36:50 |
| Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering | HOUSTON, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces the pricing of its underwritten public offering of 39,473,684 units, with each unit consisting of one share of common stock and one warrant (the “Warrants”). Each unit is being sold to the public at a price of $0.38 per unit. The gross proceeds to the Company from this offering are expected to be approximately $15 million, before deducting underwriting discounts and commissions and other estimated offering expenses. Each Warrant will be immediately exercisable, will entitle the holder to purchase one share of common stock at an exercise price of $0.38 per share and will expire five years from the date of issuance. The Company has granted the underwriter a 30-day option to purchase up to an additional 5,921,052 shares of common stock and/or warrants to purchase up to an additional 5,921,052 shares of common stock, or any combination thereof, solely to cover over-allotments, if any. | GlobeNewsWire | 2026-01-14 08:00:00 |
| Sify Technologies, Boot Barn Holdings And 3 Stocks To Watch Heading Into Monday | US stock futures down, investors focus on Sify, Boot Barn, Wealthfront, Plus Therapeutics, Solowin; Citigroup expected to report Q4 earnings. | Benzinga | 2026-01-12 02:23:10 |
| Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases | HOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announces the completion of a Type B meeting with the U.S. Food and Drug Administration (FDA) on next steps on REYOBIQ pivotal trial strategy for leptomeningeal metastases (LM). The meeting resulted in constructive discussion with the FDA regarding key elements of the potential pivotal study design for REYOBIQ in LM. | GlobeNewsWire | 2026-01-08 07:30:00 |
| Plus Therapeutics Expands CNSide Assay Platform to State of California | CNSide Diagnostics now licensed in 48 U.S. States covering over 90% of the U.S. population CNSide Diagnostics now licensed in 48 U.S. States covering over 90% of the U.S. population | GlobeNewsWire | 2025-12-11 07:30:00 |
| Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants | HOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced two new hires to its team for CNSide Diagnostics, LLC, its wholly-owned subsidiary. | GlobeNewsWire | 2025-12-09 07:30:00 |
| Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting | Cohort 1 data from multiple dose ReSPECT- Leptomeningeal Metastases (LM) trial showed no dosage limiting toxicity | GlobeNewsWire | 2025-12-04 07:30:00 |
| Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium | HOUSTON, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the acceptance of an abstract for poster spotlight (with oral) presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS), being held on December 9-12, 2025, in San Antonio, TX. Poster Spotlight Presentation: Title Rhenium (186Re) obisbemeda (rhenium nanoliposome, 186RNL) for the treatment of leptomeningeal metastases (LM): Phase 1 dose escalation study results Presenter Andrew Brenner, M.D. | GlobeNewsWire | 2025-12-01 07:30:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 8-K | 2026-02-13 | 2026-02-13 | View Filing |
| SC 13G | 2026-01-22 | 2026-01-22 | View Filing |
| 8-K | 2026-01-22 | 2026-01-22 | View Filing |
| 8-K | 2026-01-16 | 2026-01-16 | View Filing |
| 424B4 | 2026-01-14 | 2026-01-14 | View Filing |
| EFFECT | 2026-01-13 | 2026-01-14 | View Filing |
| S-1MEF | 2026-01-13 | 2026-01-13 | View Filing |
| S-1 | 2026-01-09 | 2026-01-09 | View Filing |
| 4 | 2026-01-02 | 2026-01-02 | View Filing |
| 4 | 2026-01-02 | 2026-01-02 | View Filing |
| 8-K | 2025-11-17 | 2025-11-17 | View Filing |
| 4 | 2025-11-05 | 2025-11-05 | View Filing |
| 10-Q | 2025-10-30 | 2025-10-30 | View Filing |
| 8-K | 2025-10-30 | 2025-10-30 | View Filing |
| 8-K | 2025-10-21 | 2025-10-21 | View Filing |
| 4 | 2025-10-03 | 2025-10-03 | View Filing |
| 4/A | 2025-10-03 | 2025-10-03 | View Filing |
| 4 | 2025-10-03 | 2025-10-03 | View Filing |
| 4/A | 2025-10-03 | 2025-10-03 | View Filing |
| 8-K | 2025-08-26 | 2025-08-26 | View Filing |
| 4 | 2025-08-25 | 2025-08-25 | View Filing |
| S-8 | 2025-08-22 | 2025-08-22 | View Filing |
| 4 | 2025-08-15 | 2025-08-15 | View Filing |
| 4 | 2025-08-15 | 2025-08-15 | View Filing |
| 4 | 2025-08-15 | 2025-08-15 | View Filing |
| 4 | 2025-08-15 | 2025-08-15 | View Filing |
| 4 | 2025-08-15 | 2025-08-15 | View Filing |
| 4 | 2025-08-15 | 2025-08-15 | View Filing |
| 4 | 2025-08-15 | 2025-08-15 | View Filing |
| 424B3 | 2025-08-15 | 2025-08-15 | View Filing |
| 3 | 2025-08-15 | 2025-08-15 | View Filing |
| EFFECT | 2025-08-15 | 2025-08-15 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| 8-K | 2025-08-14 | 2025-08-14 | View Filing |
| 10-Q | 2025-08-14 | 2025-08-14 | View Filing |
| 8-K | 2025-08-14 | 2025-08-14 | View Filing |
| 8-K | 2025-08-13 | 2025-08-13 | View Filing |
| 8-K | 2025-08-12 | 2025-08-12 | View Filing |
| CORRESP | 2025-08-12 | 2025-08-12 | View Filing |
| S-1 | 2025-08-12 | 2025-08-12 | View Filing |
| UPLOAD | 2025-08-05 | 2025-08-05 | View Filing |
| DRS | 2025-08-04 | 2025-08-01 | View Filing |
| DEFA14A | 2025-08-01 | 2025-08-01 | View Filing |
| SC 13G/A | 2025-07-29 | 2025-07-29 | View Filing |
| RW | 2025-07-25 | 2025-07-25 | View Filing |
| ARS | 2025-07-21 | 2025-07-21 | View Filing |
| DEF 14A | 2025-07-21 | 2025-07-21 | View Filing |
| 8-K | 2025-07-18 | 2025-07-18 | View Filing |
| PRE 14A | 2025-07-11 | 2025-07-11 | View Filing |
| SC 13G/A | 2025-06-25 | 2025-06-25 | View Filing |
| EFFECT | 2025-06-24 | 2025-06-24 | View Filing |
| RW | 2025-06-23 | 2025-06-23 | View Filing |
| 424B3 | 2025-06-23 | 2025-06-23 | View Filing |
| 8-K | 2025-06-20 | 2025-06-20 | View Filing |
| S-1/A | 2025-06-20 | 2025-06-18 | View Filing |
| S-1 | 2025-06-18 | 2025-06-17 | View Filing |
| CORRESP | 2025-06-17 | 2025-06-17 | View Filing |
| 8-K | 2025-06-17 | 2025-06-17 | View Filing |
| UPLOAD | 2025-06-13 | 2025-06-13 | View Filing |
| DRS | 2025-06-09 | 2025-06-09 | View Filing |
| 8-K | 2025-06-06 | 2025-06-06 | View Filing |
| 8-K | 2025-05-30 | 2025-05-30 | View Filing |
| 10-Q | 2025-05-30 | 2025-05-30 | View Filing |
| 8-K | 2025-05-23 | 2025-05-23 | View Filing |
| SC 13G | 2025-05-22 | 2025-05-22 | View Filing |
| 8-K | 2025-05-19 | 2025-05-19 | View Filing |
| NT 10-Q | 2025-05-15 | 2025-05-15 | View Filing |
| 144 | 2025-05-07 | 2025-05-07 | View Filing |
| 8-K | 2025-05-02 | 2025-05-02 | View Filing |
| DEFA14A | 2025-05-01 | 2025-05-01 | View Filing |
| 10-K/A | 2025-04-30 | 2025-04-30 | View Filing |
| S-3/A | 2025-04-23 | 2025-04-23 | View Filing |
| 424B3 | 2025-04-18 | 2025-04-18 | View Filing |
| 8-K | 2025-04-18 | 2025-04-18 | View Filing |
| POS AM | 2025-04-11 | 2025-04-11 | View Filing |
| UPLOAD | 2025-04-11 | 2025-04-11 | View Filing |
| DEF 14A | 2025-04-10 | 2025-04-10 | View Filing |
| S-3 | 2025-04-04 | 2025-04-04 | View Filing |
| PRER14A | 2025-04-01 | 2025-04-01 | View Filing |
| CORRESP | 2025-04-01 | 2025-04-01 | View Filing |
| 10-K | 2025-03-31 | 2025-03-31 | View Filing |
| RW | 2025-03-31 | 2025-03-31 | View Filing |
| 8-K | 2025-03-27 | 2025-03-27 | View Filing |
| UPLOAD | 2025-03-24 | 2025-03-24 | View Filing |
| SC 13G | 2025-03-18 | 2025-03-18 | View Filing |
| PRE 14A | 2025-03-14 | 2025-03-14 | View Filing |
| 424B3 | 2025-03-10 | 2025-03-10 | View Filing |
| 8-K | 2025-03-10 | 2025-03-10 | View Filing |
| 424B3 | 2025-03-04 | 2025-03-04 | View Filing |
| 8-K | 2025-03-04 | 2025-03-04 | View Filing |
| 4 | 2025-02-20 | 2025-02-20 | View Filing |
| 4 | 2025-02-20 | 2025-02-20 | View Filing |
| 4 | 2025-02-20 | 2025-02-20 | View Filing |
| 4 | 2025-02-20 | 2025-02-20 | View Filing |
| 4 | 2025-02-20 | 2025-02-20 | View Filing |
| 4 | 2025-02-20 | 2025-02-20 | View Filing |
| 4 | 2025-02-20 | 2025-02-20 | View Filing |
| 424B3 | 2025-02-18 | 2025-02-18 | View Filing |
| 8-K | 2025-02-18 | 2025-02-18 | View Filing |
| SC 13G/A | 2025-02-10 | 2025-02-10 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| MACD | 10.39% | 1.47 | 14 | 0.71 | 64.12 | 55.6 |
| ADX | 3.41% | 1.14 | 18 | 0.19 | 0.13 | 48.62 |
| Directional Movement Index Strategy | 0.67% | 1.05 | 20 | 0.6 | 1.19 | 0.64 |
| xxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxxx | xxxx | x |
| xxxxxxxxxx | xxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxx% | xxxx | xx | xxxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | x | xx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | x | xx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxxx | xxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | xx | xxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |